King Luther Capital Management Corp acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 59,662 shares of the company’s stock, valued at approximately $100,000. King Luther Capital Management Corp owned about 0.23% of Anebulo Pharmaceuticals at the end of the most recent quarter.
Analyst Ratings Changes
Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 target price on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.
Get Our Latest Analysis on Anebulo Pharmaceuticals
Anebulo Pharmaceuticals Price Performance
Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) last issued its quarterly earnings data on Friday, February 14th. The company reported ($0.09) EPS for the quarter. As a group, analysts anticipate that Anebulo Pharmaceuticals, Inc. will post -0.52 EPS for the current year.
Insiders Place Their Bets
In other news, Director Aron R. English acquired 10,101,010 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the acquisition, the director now owns 15,467,300 shares of the company’s stock, valued at $15,312,627. This represents a 188.23 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 85.90% of the stock is owned by insiders.
Anebulo Pharmaceuticals Profile
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
Featured Articles
- Five stocks we like better than Anebulo Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Find and Profitably Trade Stocks at 52-Week Lows
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.